Market Research Logo

Global Ischemic Heart Disease (IHD)Drugs Market 2015-2019

Global Ischemic Heart Disease (IHD)Drugs Market 2015-2019

About IHD

IHD is an abnormal condition of the human body marked by narrowing or blocking of the arteries that supply blood to the heart. It results from the buildup of plaque in the arteries. The condition often arises during excitement and exertion when heart requires more blood supply. This leads to recurrent chest pain and discomfort due to lack of sufficient blood supply, a condition known as angina pectoris.

Prolonged blockage of the arteries due to lack of blood supply may result in death of tissues in the heart, leading to myocardial infarction. The symptoms develop slowly, and in most cases the condition is asymptomatic until it reaches the last stages. The common indications include chest pain and shortness of breath. Treatment options are available depending on the condition of the patient. A range of medications of different classes, such as statins, antiplatelet drugs, nitrates, beta-blockers, etc. can be chosen from. Surgical procedures, such as angioplasty and coronary artery bypass graft, are also opted in serious scenarios.

Technavio analysts forecast the global IHD drugs market to grow at a CAGR of 3.61% during 2014-2019.

Covered in this Report

The report covers the present scenario and the growth prospects of the global IHD drugs market for the period 2015-2019. To calculate the market size, we consider the revenue generated from the sales of various branded therapies and generics, along with the drugs used as off-label for the treatment of IHD. IHD includes:

  • Angina pectoris
  • Myocardial infarction.
The Technavio report, namely Global IHD Drugs Market 2015-2019, is based on an in-depth market analysis, with inputs from industry experts. We covers the Americas, APAC and EMEA markets. We also discuss the key vendors operating in this market.Key Regions
  • Americas
  • EMEA
  • APAC
Key Vendors
  • AstraZeneca
  • Bayer
  • Eli Lilly
  • Novartis
  • Pfizer
  • Sanofi
Other Prominent Vendors
  • Actelion
  • Amgen
  • Baxter
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Daiichi-Sankyo
  • Eisai
  • F.Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline
  • Human Stem Cells Institute
  • Janssen Pharmaceuticals
  • Juventas Therapeutics
  • Lacer
  • Merck
  • Nuo Therapeutics
  • Ono Pharmaceutical
  • Pharmahungary Group
  • Resverlogix
  • Takeda Pharmaceutical Company
  • Taxus Cardium
  • The Medicines Company
  • United Therapeutics
Market Driver
  • Rise in Number of Patients
  • For a full and detailed list, view our report
Market Challenge
  • Delayed Diagnosis
  • For a full and detailed list, view our report
Market Trend
  • Increase in Health Awareness
  • For a full and detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Ischemic Heart Disease Drugs Market 2015-2019

Technavio recognizes the following companies as the key players in the Global Ischemic Heart Disease Drugs Market: AstraZeneca plc, Bayer AG, Eli Lilly and Co., Novartis AG, Pfizer Inc. and Sanofi SA

Commenting on the report, an analyst from Technavio’s team said: “The market has huge growth opportunities for vendors because of the growing population of individuals with IHD. To capture maximum market shares and expand the focus area, vendors are investing more on R&D.”

According to the report, the high prevalence of chronic conditions such as hypertension, diabetes, and cholesterol levels are leading to an increase in cardiovascular diseases. The people with diabetes are three to four times more likely to develop CVDs than people without diabetes.

Further, the report states that the availability of effective surgical treatments and the use of catheter based interventions pose a challenge to the growth of market. The need for specific therapeutics at the later stages of the disease leads to the increased reliance on stents and surgeries.

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
  • Disease Overview
    • Understanding the Disease
      • Table Overview of IHD
    • Etiology and Risk Factors
      • Modifiable Risk Factors
      • Non-modifiable Risk Factors
    • Pathophysiology
      • Table Pathophysiology of IHD
    • Signs and Symptoms
    • Diagnosis
      • ECG
      • Stress Testing
      • Echocardiography
      • Chest X-Ray
      • Blood Tests
      • Coronary Angiography and Cardiac Catheterization
    • Management
      • Lifestyle Changes
      • Pharmacotherapy
      • Medical Procedures
    • Epidemiology
      • Table Leading Cause of Death in World 2012
      • Table Leading Cause of Death in US 2013
    • Economic Burden
  • Pipeline Analysis
    • Table Pipeline Portfolio of IHD Drugs
    • Information on Pipeline Candidates
      • ONO-1101
      • Ranolazine
      • Autologous CD34+ stem cells
      • Generx
      • Cryocell
      • RVX-208
      • MPSK3169A
      • GS-6615
      • JVS-100
      • LA-419
      • ALD-201
  • Market Landscape
    • Market Overview
    • Market Size and Forecast
      • Table Global IHD Drugs Market 2014-2019 ($ millions)
    • Five Forces Analysis
  • Market Segmentation by Disease Class
    • Table Global IHD Drugs Market Segment by Disease Class
    • Angina Pectoris
      • Stable Angina
      • Unstable Angina
      • Prinzmetal's Angina
    • MI
      • STEMI
      • NSTEMI
  • Market Segmentation by Drug Class
    • Table Global IHD Drugs Market Segment by Drug Class
    • Anti-dyslipidemic Drugs
    • Calcium Channel Blockers
    • Beta-blockers
    • ACE Inhibitors
    • ARBs
    • Vasodilators
    • Antithrombotic Agents
  • Geographical Segmentation
    • Table Segmentation of Global IHD Drugs Market by Geography 2014
  • Buying Criteria
  • Market Growth Drivers
  • Drivers and their Impact
  • Market Challenges
  • Impact of Drivers and Challenges
  • Market Trends
  • Trends and their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
      • AstraZeneca
        • Table YoY Growth and Revenue of Atacand 2010-2014 ($ millions)
        • Table YoY Growth and Revenue of Crestor 2010-2014 ($ millions)
        • Table YoY Growth and Revenue of Seloken/Toprol-XL 2010-2014 ($ millions)
      • Bayer
        • Table YoY Growth and Revenue of Adalat 2010-2014 ($ millions)
        • Table YoY Growth and Revenue of Xarelto 2010-2014 ($ millions)
      • Eli Lilly
        • Table YoY Growth and Revenue of Effient 2010-2014 ($ millions)
      • Novartis
        • Table YoY Growth and Revenue of Diovan 2010-2014 ($ millions)
        • Table YoY Growth and Revenue of Exforge 2010-2014 ($ millions)
      • Pfizer
        • Table YoY Growth and Revenue of Caduet 2010-2014 ($ millions)
        • Table YoY Growth and Revenue of Fragmin 2010-2014 ($ millions)
        • Table YoY Growth and Revenue of Lipitor 2010-2014 ($ millions)
        • Table YoY Growth and Revenue of Norvasc 2010-2014 ($ millions)
      • Sanofi
        • Table YoY Growth and Revenue of Lovenox 2010-2014 ($ millions)
        • Table YoY Growth and Revenue of Plavix 2010-2014 ($ millions)
    • Other and Future Prominent Vendors
  • Global IHD Drugs Market: Key Takeaways
    • Table Global IHD Drugs Market: Key Takeaways
  • Key Vendor Analysis
    • AstraZeneca plc
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table AstraZeneca plc: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2011-2013
        • Table AstraZeneca plc: Business Segmentation by Revenue 2011-2013 ($ millions)
      • Sales by Geography
        • Table AstraZeneca plc: Sales by Geography 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Bayer
      • Key facts
      • Business overview
      • Business segmentation by revenue 2014
        • Table Bayer: Business segmentation by revenue 2014
      • Business segmentation by revenue 2013 and 2014
        • Table Bayer: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Geographical segmentation by revenue 2014
        • Table Bayer: Geographical segmentation by revenue 2014
      • Business strategy
      • Recent developments
      • SWOT analysis
    • Eli Lilly
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue
        • Table Eli Lilly: Business Segmentation by Revenue 2013
        • Table Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ millions)
      • Sales by Geography
        • Table Eli Lilly: Sales by Geography 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Novartis AG
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Novartis AG: Business Segmentation
      • Revenue by Business Segmentation
        • Table Novartis AG: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ millions)
      • Sales by Geography
        • Table Novartis AG: Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Pfizer
      • Key facts
      • Business overview
      • Business segmentation by revenue 2014
        • Table Pfizer: Business segmentation by revenue 2014
      • Business segmentation by revenue 2013 and 2014
        • Table Pfizer: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Geographical segmentation by revenue 2014
        • Table Pfizer: Geographical segmentation by revenue 2014
      • Business strategy
      • Key developments
      • SWOT analysis
    • Sanofi SA
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Sanofi SA: Business Segmentation
      • Revenue by Business Segmentation
        • Table Sanofi SA: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Sanofi SA: Revenue by Business Segmentation 2012 and 2013 ($ millions)
      • Sales by Geography
        • Table Sanofi SA: Sales Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
  • Other Reports in this Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report